Investing in Arvinas, Inc. (ARVN)  ➔  Intrinsic value

Prev. close$79.17 
ModelValueUpside
Chepakovich$12.26-85%
Graham-Dodd$0.94-99%
Graham$0.00-100%
Previous Close$79.17  
Valuation MethodValuePotential 
Chepakovich Model$12.26-85%recalculate
Graham-Dodd$0.94-99%recalculate
Graham Formula$0.00-100%recalculate

Latest news

Company description

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.